4-hydroxy-2-methoxy-5-thien-2-yl-benzaldehyde | 552845-89-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-hydroxy-2-methoxy-5-thien-2-yl-benzaldehyde
• 英文别名: 4-hydroxy-2-methoxy-5-thiophen-2-ylbenzaldehyde；4-Hydroxy-2-methoxy-5-thiophen-2-yl-benzaldehyde
• CAS: 552845-89-3
• 化学式: C₁₂H₁₀O₃S
• 分子量: 234.276
• InChiKey: PPXJEXIHWMKTDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  74.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-hydroxy-2-methoxy-5-thien-2-yl-benzaldehyde 在 四丁基氟化铵 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 4-(3-hydroxy-2-hydroxymethyl-propoxy)-2-methoxy-5-thiophen-2-yl-benzaldehyde
  参考文献：
  名称：

  Carboxylated, Heteroaryl-Substituted Chalcones as Inhibitors of Vascular Cell Adhesion Molecule-1 Expression for Use in Chronic Inflammatory Diseases

  摘要：

  Starting from a simple chalcone template, structure-activity relationship (SAR) studies led to a series of carboxylated, heteroaryl-substituted chalcone derivatives as novel, potent inhibitors of vascular cell adhesion molecule-1 (VCAM-1) expression. Correlations between lipophilicity determined by calculated logP values and inhibitory efficacy were observed among structurally similar compounds of the series. Various substituents were found to be tolerated at several positions of the chalcone backbone as long as the compounds fell into the right range of lipophilicity. The chalcone alpha,beta-unsaturated ketone moiety seemed to be the pharmacophore required for inhibition of VCAM-1 expression. Compound 19 showed significant antiinflammatory effects in a mouse model of allergic inflammation, indicating that this series of compounds might have therapeutic value for human asthma and other inflammatory disorders.

  DOI：

  10.1021/jm0614230
• 作为产物：
  描述：

  4-羟基-2-甲氧基苯甲醛 在 二(三叔丁基膦)钯 potassium fluoride 、 溴 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 4-hydroxy-2-methoxy-5-thien-2-yl-benzaldehyde
  参考文献：
  名称：

  Carboxylated, Heteroaryl-Substituted Chalcones as Inhibitors of Vascular Cell Adhesion Molecule-1 Expression for Use in Chronic Inflammatory Diseases

  摘要：

  Starting from a simple chalcone template, structure-activity relationship (SAR) studies led to a series of carboxylated, heteroaryl-substituted chalcone derivatives as novel, potent inhibitors of vascular cell adhesion molecule-1 (VCAM-1) expression. Correlations between lipophilicity determined by calculated logP values and inhibitory efficacy were observed among structurally similar compounds of the series. Various substituents were found to be tolerated at several positions of the chalcone backbone as long as the compounds fell into the right range of lipophilicity. The chalcone alpha,beta-unsaturated ketone moiety seemed to be the pharmacophore required for inhibition of VCAM-1 expression. Compound 19 showed significant antiinflammatory effects in a mouse model of allergic inflammation, indicating that this series of compounds might have therapeutic value for human asthma and other inflammatory disorders.

  DOI：

  10.1021/jm0614230

文献信息

• Chalcone derivatives and their use to treat diseases
  申请人：Ni Liming

  公开号：US20060189549A1

  公开（公告）日：2006-08-24

  The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.

  本发明涉及一般式化合物、药物组合物及使用该一般式化合物或其药学上可接受的盐或酯的方法，其中取代基在申请中定义。
• Process of making chalcone derivatives
  申请人：——

  公开号：US20040181075A1

  公开（公告）日：2004-09-16

  This invention is a novel methods of manufacturing chalcones that includes reacting a carbon-linked heteroaryl or heterocyclic substituted benzaldehyde with an acetophenone in a solvent or mixture of solvents in the presence of LiOMe. Also provided are new chalcones for the treatment of medical conditions.

  这项发明涉及一种新的合成查尔酮的方法，包括在溶剂或混合溶剂中，在LiOMe的存在下，将含有碳链的杂芳基或杂环取代苯甲醛与苯乙酮反应。同时提供了用于治疗医疗状况的新型查尔酮。
• [EN] PROCESS OF MAKING CHALCONE DERIVATIVES<br/>[FR] PROCEDE DE FABRICATION DE DERIVES DE CHALCONE
  申请人：ATHEROGENICS INC

  公开号：WO2004056727A3

  公开（公告）日：2004-10-14
• CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES
  申请人：Atherogenics, Inc.

  公开号：EP1465854A2

  公开（公告）日：2004-10-13
• EP1465854A4
  申请人：——

  公开号：EP1465854A4

  公开（公告）日：2005-06-08